Application of pharmaceutical profiling assays for optimization of drug-like properties

被引：0
作者：
Di, L [1 ]
Kerns, EH [1 ]
机构：
[1] Wyeth Inc, Monmouth Jct, NJ 08852 USA
来源：
CURRENT OPINION IN DRUG DISCOVERY & DEVELOPMENT | 2005年 / 8卷 / 04期
关键词：
ADME/toxicity; blood-brain barrier; cytochrome P450 inhibition; metabolism; solubility; stability; permeability; prodrugs;
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Pharmaceutical profiling assays provide an early assessment of drug-like properties, such as solubility, permeability, metabolism, stability and drug-drug interactions. This information can be used to alert project teams to potential property issues, predict and diagnose in vivo assay results, guide structure-property relationships, provide insight into structure modification, and help drug discovery teams to make informed decisions. Successful drugs can be developed when biological activities of interest and pharmaceutical properties are optimized in parallel.
引用
收藏
页码：495 / 504
页数：10
相关论文
共 32 条
  • [1] A convergent approach to cryptophycin 52 analogues: Synthesis and biological evaluation of a novel series of fragment A epoxides and chlorohydrins
    Al-Awar, RS
    Ray, JE
    Schultz, RM
    Andis, SL
    Kennedy, JH
    Moore, RE
    Liang, J
    Golakoti, T
    Subbaraju, GV
    Corbett, TH
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2003, 46 (14) : 2985 - 3007
  • [2] The design, preparation and SAR of novel small molecule sodium (Na+) channel blockers
    Ashwell, MA
    Lapierre, JM
    Kaplan, A
    Li, J
    Marr, C
    Yuan, J
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2004, 14 (09) : 2025 - 2030
  • [3] Cell culture-based models for intestinal permeability: a critique
    Balimane, PV
    Chong, S
    [J]. DRUG DISCOVERY TODAY, 2005, 10 (05) : 335 - 343
  • [4] Utility of 96 well Caco-2 cell system for increased throughput of P-gp screening in drug discovery
    Balimane, PV
    Patel, K
    Marino, A
    Chong, SH
    [J]. EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2004, 58 (01) : 99 - 105
  • [5] The conduct of in vitro and in vivo drug-drug interaction studies: A Pharmaceutical Research and Manufacturers of America (PhRMA) perspective
    Bjornsson, TD
    Callaghan, JT
    Einolf, HJ
    Fischer, V
    Gan, L
    Grimm, S
    Kao, J
    King, SP
    Miwa, G
    Ni, L
    Kumar, G
    McLeod, J
    Obach, RS
    Roberts, S
    Roe, A
    Shah, A
    Snikeris, F
    Sullivan, JT
    Tweedie, D
    Vega, JM
    Walsh, J
    Wrighton, SA
    [J]. DRUG METABOLISM AND DISPOSITION, 2003, 31 (07) : 815 - 832
  • [6] Structure-based optimization of novel azepane derivatives as PKB inhibitors
    Breitenlechner, CB
    Wegge, T
    Berillon, L
    Graul, K
    Marzenell, M
    Friebe, WG
    Thomas, U
    Schumacher, R
    Huber, R
    Engh, RA
    Masjost, B
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2004, 47 (06) : 1375 - 1390
  • [7] Experimental design on single-time-point high-throughput microsomal stability assay
    Di, L
    Kerns, EH
    Gao, N
    Li, SQ
    Huang, YP
    Bourassa, JL
    Huryn, DM
    [J]. JOURNAL OF PHARMACEUTICAL SCIENCES, 2004, 93 (06) : 1537 - 1544
  • [8] Optimization of a higher throughput microsomal stability screening assay for profiling drug discovery candidates
    Di, L
    Kerns, EH
    Hong, Y
    Kleintop, TA
    McConnell, OJ
    Huryn, DM
    [J]. JOURNAL OF BIOMOLECULAR SCREENING, 2003, 8 (04) : 453 - 462
  • [9] DI L, 2005, IN PRESS INT J PHARM
  • [10] Key factors in the rising cost of new drug discovery and development
    Dickson, M
    Gagnon, JP
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2004, 3 (05) : 417 - 429
1234